

# Stephen Palmer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5873738/publications.pdf>

Version: 2024-02-01

53  
papers

1,302  
citations

361413

20  
h-index

377865

34  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2149  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple Myeloma. <i>Value in Health</i> , 2022, 25, 595-604.	0.3	2
2	Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness. <i>Medical Decision Making</i> , 2021, 41, 165-178.	2.4	8
3	Classifying information-sharing methods. <i>BMC Medical Research Methodology</i> , 2021, 21, 107.	3.1	6
4	Cost-effectiveness of point-of-care creatinine testing to assess kidney function prior to contrast-enhanced computed tomography imaging. <i>European Journal of Radiology</i> , 2021, 142, 109872.	2.6	0
5	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. <i>Health Technology Assessment</i> , 2021, 25, 1-228.	2.8	7
6	How should we assess the clinical and cost effectiveness of histology independent cancer drugs?. <i>BMJ</i> , The, 2020, 368, l6435.	6.0	14
7	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. <i>European Journal of Health Economics</i> , 2020, 21, 1421-1437.	2.8	38
8	Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?. <i>Value in Health</i> , 2020, 23, 1613-1621.	0.3	57
9	After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?. <i>Pharmacoeconomics</i> , 2020, 38, 247-257.	3.3	13
10	Economic evaluations in migraine: systematic literature review and a novel approach. <i>Journal of Medical Economics</i> , 2020, 23, 864-876.	2.1	9
11	Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2020, 24, 1-306.	2.8	31
12	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation. <i>Health Technology Assessment</i> , 2020, 24, 1-248.	2.8	12
13	Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 131-139.	3.3	7
14	Time Horizons in Cost Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 582.	7.4	3
15	Migraine day frequency in migraine prevention: longitudinal modelling approaches. <i>BMC Medical Research Methodology</i> , 2019, 19, 20.	3.1	8
16	The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 1081-1091.	3.3	5
17	Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Advances in Therapy</i> , 2019, 36, 950-961.	2.9	19
18	Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology. <i>Pharmacoeconomics</i> , 2019, 37, 727-737.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. <i>Journal of Medical Economics</i> , 2018, 21, 666-675.	2.1	36
20	Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. <i>Medical Decision Making</i> , 2018, 38, 200-211.	2.4	196
21	Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19000-e19000.	1.6	1
22	High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2018, 22, 1-172.	2.8	16
23	Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation. <i>Health Technology Assessment</i> , 2018, 22, 1-260.	2.8	6
24	Estimating Long-Term Survival in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Blood</i> , 2018, 132, 3556-3556.	1.4	0
25	How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. <i>Medical Decision Making</i> , 2017, 37, 148-161.	2.4	18
26	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. <i>Health Economics (United Kingdom)</i> , 2017, 26, 109-123.	1.7	52
27	How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 767-776.	3.3	14
28	Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison. <i>Advances in Therapy</i> , 2017, 34, 495-512.	2.9	5
29	The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. <i>Health Technology Assessment</i> , 2017, 21, 1-204.	2.8	95
30	Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-326.	2.8	21
31	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-244.	2.8	16
32	Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 125-140.	4.0	49
33	The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 1101-1110.	3.3	2
34	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. <i>Value in Health</i> , 2016, 19, 885-891.	0.3	38
35	The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 901-912.	3.3	7
36	Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. <i>Value in Health</i> , 2016, 19, 138-144.	0.3	24

#	ARTICLE	IF	CITATIONS
37	Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. <i>Advances in Therapy</i> , 2016, 33, 643-657.	2.9	10
38	Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 587-596.	3.3	3
39	Using electronic health records to predict costs and outcomes in stable coronary artery disease. <i>Heart</i> , 2016, 102, 755-762.	2.9	26
40	Tumour necrosis factor- $\alpha$ inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-334.	2.8	62
41	The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial. <i>Health Technology Assessment</i> , 2016, 20, 1-64.	2.8	31
42	Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. <i>Value in Health</i> , 2015, 18, 865-875.	0.3	17
43	Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses. <i>Medical Decision Making</i> , 2015, 35, 608-621.	2.4	16
44	Screening for psychological and mental health difficulties in young people who offend: a systematic review and decision model. <i>Health Technology Assessment</i> , 2015, 19, 1-128.	2.8	5
45	A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. <i>Health Technology Assessment</i> , 2015, 19, 1-174.	2.8	55
46	Clinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems: a systematic review and meta-analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-348.	2.8	32
47	Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-220.	2.8	26
48	Optimizing the Position and Use of Omalizumab for Severe Persistent Allergic Asthma Using Cost-Effectiveness Analysis. <i>Value in Health</i> , 2014, 17, 772-782.	0.3	36
49	The added clinical and economic value of diagnostic testing for epilepsy surgery. <i>Epilepsy Research</i> , 2014, 108, 775-781.	1.6	16
50	Dronedaron per il trattamento della fibrillazione atriale. <i>Pharmacoeconomics Italian Research Articles</i> , 2013, 15, 91-100.	0.2	0
51	The Cost-Effectiveness of Cognitive Behavior Therapy for Borderline Personality Disorder: Results from the BOSCOT Trial. <i>Journal of Personality Disorders</i> , 2006, 20, 466-481.	1.4	60
52	Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service?. <i>International Journal of Cardiology</i> , 2005, 100, 229-240.	1.7	39
53	Common Errors and Controversies in Pharmacoeconomic Analyses. <i>Pharmacoeconomics</i> , 1998, 13, 659-666.	3.3	29